RxDoctor Payments Data

Imade Osaghae, PA

Medical · Fresno, CANPI 1861895773

Payments from drug & device makers

$837in general payments, 2019–2025

Across 33 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shield Therapeutics Inc$174
  • Lilly USA, LLC$128
  • Dynavax Technologies Corporation$117
  • Exact Sciences$78
  • Amgen$73
  • Regeneron Healthcare Solutions, Inc.$55
  • plus $212 from 9 others

What the payments were for

  • Food & beverage$837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$837 in reported general payments places this provider in the 60th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$620
Medicare patients
39
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$27,589
OzempicSemaglutide18$17,474
LinzessLinaclotide11$6,362
Atorvastatin Calcium211$2,081
Albuterol Sulfate HfaAlbuterol Sulfate47$1,479
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,107
Metformin Hcl109$697
Amlodipine Besylate101$697
Gabapentin57$662
Lisinopril94$656
Baclofen43$637
Tamsulosin Hcl29$603
Losartan Potassium70$497
Pravastatin Sodium31$433
Pioglitazone Hcl33$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$26$17,47418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,087 medical providers in California.

Other medical in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →